Balaji Amines Limited has scheduled a plant visit followed by a management meet with analysts and investors on June 5, 2026. The event will take place in Solapur, Maharashtra, providing market participants an opportunity to review the company's operations firsthand. The interaction is structured as a physical meeting, allowing for direct engagement with the company's management team.

Discussions during the visit will be based strictly on publicly available information. The company explicitly stated that no unpublished price sensitive information (UPSI) relating to Balaji Amines Limited will be disclosed during these interactions. This ensures compliance with regulatory standards regarding fair disclosure and information symmetry.

The schedule for the event is outlined below:

This disclosure was submitted to the exchanges pursuant to Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company noted that changes to the schedule may occur due to exigencies on the part of the participants or the company. The latest investor presentation is available on the company's official website.

Balaji Amines Limited has announced its financial results for the quarter and fiscal year ended March 31, 2026. The company reported a steady performance for FY26, supported by stable demand and improved cost efficiencies. The management also provided updates on its strategic expansion projects and future outlook during the earnings conference call held on May 18, 2026.

Financial Performance for Q4 FY26

Consolidated total revenue for Q4 FY26 stood at INR403 crores, compared to INR361 crores in Q4 FY25, registering a year-on-year growth of 12%. Profit after-tax (PAT) for the quarter increased significantly to INR65 crores from INR40 crores in the corresponding period of the previous year.

The company's operational efficiency improved, with consolidated EBITDA rising to INR102 crores from INR68 crores in Q4 FY25. Consequently, the EBITDA margin expanded to 25% in Q4 FY26 from 19% in the previous year. Diluted EPS for the quarter stood at INR19.99 per equity share.

Annual Performance and Balance Sheet

For the full fiscal year FY26, consolidated total revenue reached INR1,454 crores, a slight increase from INR1,430 crores in FY25. Consolidated PAT for the year stood at INR169 crores, reflecting a growth of 7% over INR159 crores in the previous year. The EBITDA margin for FY26 improved to 20% from 19% in FY25.

The company's balance sheet remained robust, with consolidated net worth increasing to INR2,152 crores as of March 2026 from INR2,018 crores in March 2025. Consolidated debt was reported at INR133 crores, primarily attributed to ongoing expansion activities. On a stand-alone basis, the company continues to maintain a zero-debt status.

Operational Highlights and Expansion Updates

Total consolidated sales volume for Q4 FY26 was 27,341 MT, compared to 25,871 MT in Q4 FY25. Management noted that production was briefly impacted in March 2026 due to external geopolitical factors but was managed effectively through inventory planning.

The company provided updates on its key growth projects. The Dimethyl Ether (DME) plant at Unit 4 is expected to be commissioned in Q1 FY27. The N-Methyl Morpholine (NMM) project with a capacity of 5,000 TPA and the improved process Acetonitrile (ACN) plant are also under execution, with commissioning expected during FY27.

Additionally, Balaji Specialty Chemicals Limited is undertaking a major expansion of around INR750 crores. The brownfield project for EDA-based value-added products is slated for commissioning in the first half of FY27, while the greenfield project at MIDC, Chincholi, is expected to be commissioned in Q4 FY27.